Nuvectis Pharma to present NXP900 data at 2026 cancer research meeting Mar 31, 2026 08:01AM
Nuvectis Pharma (NVCT) files $150M mixed shelf Feb 13, 2026 04:05PM
H.C. Wainwright Reiterates Buy Rating on Nuvectis Pharma (NVCT) Dec 3, 2025 06:44AM
H.C. Wainwright Reiterates Buy Rating on Nuvectis Pharma (NVCT) Oct 28, 2025 06:44AM
Nuvectis Pharma, Inc. (NVCT) Misses Q2 EPS by 5c Aug 5, 2025 09:11AM


Aug 4, 2025 09:54AM Nuvectis Pharma (NVCT) PT Lowered to $10 at H.C. Wainwright
Jul 8, 2025 08:03AM Nuvectis Pharma completes drug interaction study for NXP900 cancer drug
May 6, 2025 04:35PM Nuvectis Pharma, Inc. (NVCT) Tops Q1 EPS by 53c
Mar 17, 2025 01:08AM Laidlaw Starts Nuvectis Pharma (NVCT) at Buy
Mar 4, 2025 08:02AM Nuvectis Pharma (NVCT) Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy
Feb 5, 2025 09:02AM Nuvectis Pharma (NVCT) prices 2.7 million shares at $5.00
Feb 4, 2025 04:05PM Nuvectis Pharma (NVCT) Announces Proposed Share Offering
Nov 14, 2024 07:01AM Nuvectis Pharma (NVCT) Reports Encouraging NXP800 Interim Data
Nov 5, 2024 04:05PM Nuvectis Pharma, Inc. (NVCT) Tops Q3 EPS by 1c
Aug 29, 2024 08:01AM Nuvectis Pharma (NVCT) Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers